CVRx, Inc. is a privately held company founded in 2001 and headquartered in Minneapolis. The company has developed the Barostim neo™, an implantable system designed to treat hypertension and heart failure. Barostim neo received CE marking for the treatment of hypertension in Europe. It is under clinical evaluation for the treatment of heart failure in Europe and the United States and under clinical evaluation for the treatment of hypertension in the United States. CVRx has treated more than 625 patients with its patented devices.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/11/13 | $29,600,000 |
BBT Fund Johnson & Johnson Innovation SightLine Partners | undisclosed | |
| 10/30/13 | $12,000,000 | Series F |
DaVita HealthCare Partners Ysios Capital | undisclosed |
| 08/09/16 | $113,000,000 |
Action Potential Venture Capital Gilde Healthcare Partners Johnson & Johnson Innovation Oxford Finance Windham Venture Partners Ysios BioFund | undisclosed |
